CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Sales	$ 53,152,141	$ 53,124,050	$ 160,764,396	$ 150,817,850
Cost of sales	17,165,897	16,921,284	49,904,917	48,767,900
Gross profit	35,986,244	36,202,766	110,859,479	102,049,950
Operating expenses
Selling expenses	2,551,245	3,545,378	6,829,365	12,536,727
General and administrative expenses	9,218,798	11,599,779	26,771,966	26,677,945
Research and development expenses	1,053,383	637,397	2,801,625	2,277,474
Income from operations	23,162,818	20,420,212	74,456,523	60,557,804
Other income/ (expenses)
Equity in income of an equity method investee	642,579	744,976	1,382,524	2,219,279
Change in fair value of derivative liabilities	0	0	0	1,769,140
Interest expense	(306,656)	(223,992)	(741,569)	(990,190)
Interest income	1,320,263	561,761	2,964,082	1,870,873
Other income, net	0	449,815	0	347,029
Total other income, net	1,656,186	1,532,560	3,605,037	5,216,131
Earnings before income tax expense	24,819,004	21,952,772	78,061,560	65,773,935
Income tax expense	4,871,041	3,479,683	13,223,592	9,990,014
Net income	19,947,963	18,473,089	64,837,968	55,783,921
Less: Net income attributable to noncontrolling interest	5,251,940	4,855,939	19,064,159	16,370,694
Net income attributable to China Biologic Products, Inc.	14,696,023	13,617,150	45,773,809	39,413,227
Net income per share of common stock:
Basic	$ 0.55	$ 0.51	$ 1.71	$ 1.51
Diluted	$ 0.53	$ 0.50	$ 1.64	$ 1.41
Weighted average shares used in computation:
Basic	26,288,154	26,546,929	26,649,563	26,009,707
Diluted	27,449,081	27,018,904	27,780,005	26,741,713
Net income	19,947,963	18,473,089	64,837,968	55,783,921
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	1,985,434	(86,731)	7,810,690	1,226,404
Comprehensive income	21,933,397	18,386,358	72,648,658	57,010,325
Less: Comprehensive income attributable to noncontrolling interest	5,586,905	4,926,035	20,469,852	16,692,803
Comprehensive income attributable to China Biologic Products, Inc.	$ 16,346,492	$ 13,460,323	$ 52,178,806	$ 40,317,522